Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
April 24, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including...
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
April 16, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext...
Vivoryon Therapeutics N.V. Announces Changes to Board Composition
March 15, 2024 02:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a...
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
March 04, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease VIVIAD Phase 2b study did not meet its primary and key secondary...
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
January 08, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
December 06, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress VIVIAD and VIVA-MIND studies both advancing as planned at 600mg twice daily following...
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
November 28, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Halle (Saale) / Munich, Germany, November 28, 2023 - Vivoryon Therapeutics N.V....
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
November 07, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)...
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
October 26, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Both VIVIAD and VIVA-MIND...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
October 23, 2023 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed...